The Experts below are selected from a list of 78 Experts worldwide ranked by ideXlab platform
E Mcveigh - One of the best experts on this subject based on the ideXlab platform.
-
induction of ovulation in women undergoing assisted reproductive techniques recombinant human fsh follitropin alpha versus highly purified urinary fsh Urofollitropin hp
Human Reproduction, 2000Co-Authors: E Lenton, A Soltan, J Hewitt, A Thomson, W Davies, N Ashraf, V Sharma, L Jenner, W Ledger, E McveighAbstract:This multicentre, open, randomized, study compared the efficacy and safety of recombinant follicle stimulating hormone (rFSH; follitropin alpha) with highly purified urinary human FSH (uFSH; Urofollitropin HP) in women undergoing ovulation induction for assisted reproductive techniques. Following long down-regulation with buserelin, patients received two ampoules of 75 IU (150 IU) s.c. rFSH or highly purified uFSH for 6 days, after which the dose could be increased until they fulfilled the criteria for human chorionic gonadotrophin (HCG) administration. Of 168 patients recruited, 155 received at least one dose of FSH, and 137 received HCG [68: rFSH (85%); 69: uFSH (92%)]. Following oocyte retrieval and fertilization, up to three embryos were replaced/patient and luteal support was given. The mean number of oocytes retrieved/patient was 10.2 +/- 6.0 for rFSH patients compared with 10.8 +/- 6.1 in the uFSH group (not significant). There was a trend towards fewer ampoules used (22.3 +/- 6.5 versus 24.3 +/- 6.5), higher pregnancy (44.3 versus 41.4%) and live birth rates (33.8 versus 26.7%), as well as a lower miscarriage rate (0.0 versus 16.7%) in favour of rFSH. However, no significant differences in efficacy parameters were recorded. Ovarian hyperstimulation syndrome occurred in 8.6% and 7.9% of rFSH and uFSH patients respectively. In conclusion, this protocol was effective in inducing multiple follicular development and high numbers of oocytes were retrieved with both drugs.
E Lenton - One of the best experts on this subject based on the ideXlab platform.
-
induction of ovulation in women undergoing assisted reproductive techniques recombinant human fsh follitropin alpha versus highly purified urinary fsh Urofollitropin hp
Human Reproduction, 2000Co-Authors: E Lenton, A Soltan, J Hewitt, A Thomson, W Davies, N Ashraf, V Sharma, L Jenner, W Ledger, E McveighAbstract:This multicentre, open, randomized, study compared the efficacy and safety of recombinant follicle stimulating hormone (rFSH; follitropin alpha) with highly purified urinary human FSH (uFSH; Urofollitropin HP) in women undergoing ovulation induction for assisted reproductive techniques. Following long down-regulation with buserelin, patients received two ampoules of 75 IU (150 IU) s.c. rFSH or highly purified uFSH for 6 days, after which the dose could be increased until they fulfilled the criteria for human chorionic gonadotrophin (HCG) administration. Of 168 patients recruited, 155 received at least one dose of FSH, and 137 received HCG [68: rFSH (85%); 69: uFSH (92%)]. Following oocyte retrieval and fertilization, up to three embryos were replaced/patient and luteal support was given. The mean number of oocytes retrieved/patient was 10.2 +/- 6.0 for rFSH patients compared with 10.8 +/- 6.1 in the uFSH group (not significant). There was a trend towards fewer ampoules used (22.3 +/- 6.5 versus 24.3 +/- 6.5), higher pregnancy (44.3 versus 41.4%) and live birth rates (33.8 versus 26.7%), as well as a lower miscarriage rate (0.0 versus 16.7%) in favour of rFSH. However, no significant differences in efficacy parameters were recorded. Ovarian hyperstimulation syndrome occurred in 8.6% and 7.9% of rFSH and uFSH patients respectively. In conclusion, this protocol was effective in inducing multiple follicular development and high numbers of oocytes were retrieved with both drugs.
Torbjorn Hillensjo - One of the best experts on this subject based on the ideXlab platform.
-
serum fsh levels in women with polycystic ovary syndrome during ovulation induction using down regulation and Urofollitropin
European Journal of Endocrinology, 1997Co-Authors: Margareta Fridstrom, Peter Sjoblom, Ake Pousette, Torbjorn HillensjoAbstract:Objective: To evaluate retrospectively the use of serum FSH levels and to correlate them with follicular growth in a clinical ovulation induction program. Methods: Twenty women with infertility due to anovulation associated with polycystic ovary syndrome (PCOS) were studied. The patients were down-regulated with a long GnRH agonist protocol and stimulated with purified Urofollitropin, using a low-dose step-up regimen. Repeated serum samples were drawn and transvaginal ultrasound scans were performed. During the exogenous FSH therapy serum FSH levels resulting in continuous follicular growth were analyzed, as well as the rates of ovulation, pregnancy, cancellation and conversion to in vitro fertilization (IVF). Results : Thirty-two out of fifty treatment cycles led to ovulation, resulting in five term pregnancies. Eight cycles were converted to IVF/embryo transfer due to multiple follicular growth. They resulted in two pregnancies. Ten cycles were cancelled because of impaired follicular growth. The serum FSH levels (median 6 IU/l) resulting in continuous growth of the follicles were relatively stable within patients (variation 15%) but varied considerably between patients (45%). The relationship between FSH dose and serum level was different for lean and obese PCOS patients after subcutaneously injected Urofollitropin. Conclusions: There seems to be a difference in resorption/metabolism between lean and obese PCOS patients with regard to s.c. injected FSH. The intra-patient coefficient of variation (C.V.) of the serum FSH response level was quite low, as was the C.V. of the FSH dose at the response level. This allowed a more rapid dose adjustment in subsequent cycles. Analysis of serum FSH during induction of ovulation with gonadotropins seems to be of limited value in clinical programs.
D Mendola - One of the best experts on this subject based on the ideXlab platform.
-
comparative assessment of the consistency and quality of a highly purified fsh extracted from human urine Urofollitropin and a recombinant human fsh follitropin α
Reproductive Biomedicine Online, 2006Co-Authors: M Lispi, R Bassett, C Crisci, M Mancinelli, F Martelli, D Ceccarelli, C De Bellis, D MendolaAbstract:Abstract The revolutionary development of biotechnology-derived therapeutic proteins has provided the expected improvements in quality, purity and consistency, as demonstrated in recombinant human FSH (rhFSH). However, the development of urine-derived gonadotrophins has not always shown comparable improvements. More recently, highly purified urine-derived FSH (uFSH-HP) products have become widely available. The relative purity, level of urine-derived contaminants, and consistency of one such highly purified human uFSH (uhFSH) (Urofollitropin) has been assessed and directly compared with rhFSH (follitropin α). It has been demonstrated that the highly purified Urofollitropin contains variable levels of urine-derived contaminant proteins and demonstrates a variable level of FSH purity, FSH isoforms, and delivered dose. These variable factors may contribute to the control of ovarian stimulation. The relative purity, variable consistency and the presence of contaminants indicates that the Urofollitropin is, at best, a partially purified uFSH that is not able to meet the quality attributes of follitropin α (rhFSH).
Bart C J M Fauser - One of the best experts on this subject based on the ideXlab platform.
-
recombinant follicle stimulating hormone fsh puregon is more efficient than urinary fsh metrodin in women with clomiphene citrate resistant normogonadotropic chronic anovulation a prospective multicenter assessor blind randomized clinical trial
Fertility and Sterility, 1998Co-Authors: Herjan Coelingh J T Bennink, Bart C J M FauserAbstract:Objective: To compare the safety and efficacy of recombinant FSH (follitropin beta, Puregon; NV Organon, Oss, the Netherlands) and urinary FSH (Urofollitropin, Metrodin; Ares-Serono, Geneva, Switzerland). Design: A prospective, multicenter, assessor-blind, randomized, clinical trial. Setting: Twelve European infertility clinics. Patient(s): One hundred seventy-two women (recombinant FSH: n = 105; urinary FSH: n = 67) with clomiphene citrate-resistant normogonadotropic chronic anovulation (World Health Organization group II). Intervention(s): Eligible subjects were randomized (ratio of recombinant to urinary FSH, 3:2) and treated for a maximum of three cycles. A low-dose step-up regimen was used, with 75 IU of FSH given IM daily for a maximum of 14 days and, if needed, weekly increments of half an ampule given thereafter until the threshold dose for follicular development was achieved. Main Outcome Measure(s): Cumulative ovulation rate after three cycles, total FSH dose, and treatment period needed to achieve ovulation. Result(s): The cumulative ovulation rates after three treatment cycles were 95% and 96% for the recombinant and urinary FSH groups, respectively. Overall, ovulation was seen in 155 of 223 treatment cycles (69.5%) in the recombinant FSH group, compared with 92 of 138 treatment cycles (66.7%) in the urinary FSH group. In the first cycle, a statistically significantly lower total dose (750 versus 1,035 IU) and a shorter treatment period (10 versus 13 days) were needed in the recombinant FSH group to reach ovulation. Only one case of ovarian hyperstimulation syndrome led to hospitalization. Two sets of twins (one in each treatment group) and one set of triplets (in the recombinant FSH group) were born. Conclusion(s): Recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in inducing follicular development.